References
- Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13(6):537–566
- Japanese Society of Nephrology. CKD treatment guidance 2012 [Article in Japanese]. Tokyo: Tokyo Igakusha; 2012
- Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–1029
- Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–650
- Okamoto K. A new-generation uric acid production inhibitor febuxostat – comparison of the XO inhibition mechanism with allopurinol [Article in Japanese]. Yakuri to Chiryo. 2010;38(11):955–962
- Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13–S18
- Becker MA, Schumacher Jr HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63 . doi: 10.1186/ar2978
- Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548
- Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med. 2005;353:2450–2461
- Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheum. 2009;36(6):1273–1282
- Hanratty R, Chonchol M, Dickinson LM, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant. 2010;25(3):801–807
- Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7–13
- Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–146
- Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin--angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–1242
- Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36(1):43–49
- Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–932
- Hiramitsu S, Ishiguro Y, Matsuyama H, et al. Investigation of the utility of febuxostat (Feburic® tablet) in patients with hyperuricemia – multi-center collaborative study by general practitioners [Article in Japanese]. Blood Pressure. 2012;19:395–402
- Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446
- Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393
- Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med. 2011;51(1):179–184
- Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549–556
- Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia--reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266–272